Supplementary Figure S4 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1

Key Points

Results indicate improved overall response rates in women receiving camizestrant with CDK4/6 inhibitors, highlighting combinatorial efficacy.
Median progression-free survival was significantly extended for the cohort treated with camizestrant, indicating prolonged benefit.
Subgroup analysis across pooled data from various trials provides comprehensive insight into treatment effectiveness.
These findings support the potential for integrating camizestrant in treatment regimens for advanced breast cancer.

Analysis reports ORR and PFS in women with advanced breast cancer, suggesting effective combinations with CDK4/6 inhibitors.

ORR, CBR24, and median PFS for subgroup analysis across pooled camizestrant 75 mg combination arms

No takes yet. Share an insight, caveat, or question.

Baird et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share